Literature DB >> 18694335

Bacterial endosymbiosis is widely present among zygomycetes but does not contribute to the pathogenesis of mucormycosis.

Ashraf S Ibrahim1, Teclegiorgis Gebremariam, Mingfu Liu, Georgios Chamilos, Dimitrios Kontoyiannis, Richard Mink, Kyung J Kwon-Chung, Yue Fu, Christopher D Skory, John E Edwards, Brad Spellberg.   

Abstract

Environmental isolates of the fungus Rhizopus have been shown to harbor a bacterial endosymbiont (Burkholderia) that produces rhixozin, a plant mycotoxin. We sought to define the role of rhizoxin production by endosymbionts in the pathogenesis of mucormycosis. Endosymbiotic bacteria were identified by polymerase chain reaction in 15 (54%) of 28 clinical isolates of Zygomycetes, with 33% of the bacterial strains showing 87% identity to Burkholderia 16S rDNA. The presence of rhizoxin in myclial extracts from fungi harboring bacteria was confirmed by high-performance liquid chromatography analysis. However, fungal strains with or without endosymbionts did not differ in their ability to cause endothelial cell injury in vitro, nor did antibiotic-mediated eradication of endosymbionts and rhizoxin production decrease the virulence of fungal strains in mice or flies. In summary, although bacterial endosymbiosis is widely detected in clinical isolates of Zygomycetes, including Rhizopus oryzae strains, we found no evidence that bacterial endosymbionts and rhizoxin contribute to the pathogenesis of mucormycosis in the models studied.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18694335      PMCID: PMC2729545          DOI: 10.1086/591461

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  27 in total

1.  Preclinical and phase I studies with rhizoxin to apply a pharmacokinetically guided dose-escalation scheme.

Authors:  M A Graham; D Bissett; A Setanoians; T Hamilton; D J Kerr; R Henrar; S B Kaye
Journal:  J Natl Cancer Inst       Date:  1992-04-01       Impact factor: 13.506

Review 2.  Improved outcome of zygomycosis in patients with hematological diseases?

Authors:  B Gleissner; A Schilling; I Anagnostopolous; I Siehl; E Thiel
Journal:  Leuk Lymphoma       Date:  2004-07

3.  Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi.

Authors:  Shahid Husain; Barbara D Alexander; Patricia Munoz; Robin K Avery; Sally Houston; Timothy Pruett; Richard Jacobs; Edward A Dominguez; Jan G Tollemar; Katherine Baumgarten; Chen M Yu; Marilyn M Wagener; Peter Linden; Shimon Kusne; Nina Singh
Journal:  Clin Infect Dis       Date:  2003-07-09       Impact factor: 9.079

4.  Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzae.

Authors:  Ashraf S Ibrahim; Valentina Avanessian; Brad Spellberg; John E Edwards
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

5.  Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria.

Authors:  E A Jaffe; R L Nachman; C G Becker; C R Minick
Journal:  J Clin Invest       Date:  1973-11       Impact factor: 14.808

6.  Iteration as programmed event during polyketide assembly; molecular analysis of the aureothin biosynthesis gene cluster.

Authors:  Jing He; Christian Hertweck
Journal:  Chem Biol       Date:  2003-12

7.  Studies on macrocyclic lactone antibiotics. XI. Anti-mitotic and anti-tubulin activity of new antitumor antibiotics, rhizoxin and its homologues.

Authors:  M Takahashi; S Iwasaki; H Kobayashi; S Okuda; T Murai; Y Sato; T Haraguchi-Hiraoka; H Nagano
Journal:  J Antibiot (Tokyo)       Date:  1987-01       Impact factor: 2.649

8.  Rhizoxin, a macrocyclic lactone antibiotic, as a new antitumor agent against human and murine tumor cells and their vincristine-resistant sublines.

Authors:  T Tsuruo; T Oh-hara; H Iida; S Tsukagoshi; Z Sato; I Matsuda; S Iwasaki; S Okuda; F Shimizu; K Sasagawa
Journal:  Cancer Res       Date:  1986-01       Impact factor: 12.701

9.  Studies on macrocyclic lactone antibiotics. VIII. Absolute structures of rhizoxin and a related compound.

Authors:  S Iwasaki; M Namikoshi; H Kobayashi; J Furukawa; S Okuda; A Itai; A Kasuya; Y Iitaka; Z Sato
Journal:  J Antibiot (Tokyo)       Date:  1986-03       Impact factor: 2.649

10.  Phase II clinical trials with rhizoxin in breast cancer and melanoma. The EORTC Early Clinical Trials Group.

Authors:  A R Hanauske; G Catimel; S Aamdal; W ten Bokkel Huinink; R Paridaens; N Pavlidis; S B Kaye; A te Velde; J Wanders; J Verweij
Journal:  Br J Cancer       Date:  1996-02       Impact factor: 7.640

View more
  28 in total

Review 1.  Bacterial-fungal interactions: hyphens between agricultural, clinical, environmental, and food microbiologists.

Authors:  P Frey-Klett; P Burlinson; A Deveau; M Barret; M Tarkka; A Sarniguet
Journal:  Microbiol Mol Biol Rev       Date:  2011-12       Impact factor: 11.056

Review 2.  Update on mucormycosis pathogenesis.

Authors:  Ashraf S Ibrahim; Dimitrios P Kontoyiannis
Journal:  Curr Opin Infect Dis       Date:  2013-12       Impact factor: 4.915

3.  The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice.

Authors:  Mingfu Liu; Brad Spellberg; Quynh T Phan; Yue Fu; Yong Fu; Amy S Lee; John E Edwards; Scott G Filler; Ashraf S Ibrahim
Journal:  J Clin Invest       Date:  2010-05-17       Impact factor: 14.808

Review 4.  Pathogenesis of mucormycosis.

Authors:  Ashraf S Ibrahim; Brad Spellberg; Thomas J Walsh; Dimitrios P Kontoyiannis
Journal:  Clin Infect Dis       Date:  2012-02       Impact factor: 9.079

5.  CotH3 mediates fungal invasion of host cells during mucormycosis.

Authors:  Teclegiorgis Gebremariam; Mingfu Liu; Guanpingsheng Luo; Vincent Bruno; Quynh T Phan; Alan J Waring; John E Edwards; Scott G Filler; Michael R Yeaman; Ashraf S Ibrahim
Journal:  J Clin Invest       Date:  2013-12-20       Impact factor: 14.808

6.  Bicarbonate correction of ketoacidosis alters host-pathogen interactions and alleviates mucormycosis.

Authors:  Teclegiorgis Gebremariam; Lin Lin; Mingfu Liu; Dimitrios P Kontoyiannis; Samuel French; John E Edwards; Scott G Filler; Ashraf S Ibrahim
Journal:  J Clin Invest       Date:  2016-05-09       Impact factor: 14.808

Review 7.  Inter-kingdom encounters: recent advances in molecular bacterium-fungus interactions.

Authors:  Mika T Tarkka; Alain Sarniguet; Pascale Frey-Klett
Journal:  Curr Genet       Date:  2009-04-01       Impact factor: 3.886

8.  Characterization of Burkholderia rhizoxinica and B. endofungorum isolated from clinical specimens.

Authors:  Jay E Gee; Mindy B Glass; Gerald Lackner; Leta O Helsel; Maryam Daneshvar; Dannie G Hollis; Jean Jordan; Roger Morey; Arnold Steigerwalt; Christian Hertweck
Journal:  PLoS One       Date:  2011-01-18       Impact factor: 3.240

9.  Impact of endofungal bacteria on infection biology, food safety, and drug development.

Authors:  Gerald Lackner; Christian Hertweck
Journal:  PLoS Pathog       Date:  2011-06-30       Impact factor: 6.823

10.  Invasive mold infections: virulence and pathogenesis of mucorales.

Authors:  Giulia Morace; Elisa Borghi
Journal:  Int J Microbiol       Date:  2011-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.